glp-1 gastric intestinal obstruction class action in michigan semaglutide digestive blockage gastrointestinal Subocclusive ileus following off-label high-dose semaglutide use in: Endocrinology, Diabetes & Metabolism Case Reports Volume 2025 Issue 4 (2025) Lawsuit filed against Patients claim blindness, bowel injuries

Food and Drug Administration (FDA) in June 2019 under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women

Stay focused

However, GLP-1 medications are not a substitute for a complete heart-health plan

Ongoing Monitoring and Support We provide continued follow-up to monitor progress, ensure safety, and optimize outcomes

Its 5 extra minutes in a med check: Hows your weight

It represents a key first step in our efforts to bring this medicine to market and underscores our ambition to increase competition and expand affordability in a critical area of healthcare need. Eli Lilly has patent protection in the United States for Mounjaro and Zepbound until 2036